Results from a phase II study (ATLANTIC) showed preferential activityin tumors with PD-L1 expression.43 PD-L1 positivity was defined as at least 25% of tumor cells with membranousstaining for PD-L1. This evidence concerns the gene CD274 and neoplasm.